✦ LIBER ✦

354 Taxol® (paclitaxel) 225 MG/M2 by 3-hour infusion without G-CSF as a first line therapy in patients with metastatic breast cancer (MBC)

✍ Scribed by J. Bonneterre; M. Tubiana-Hulm; Ph. Chollet; B. Chevallier; P. Fumoleau; P. Kerbrat; B. Vie; D. Khayat; N. Tubiana; C. Lejeune; A. Le Grand; J.A. Soares; B. Pellae-Cosset

Book ID: 116167109
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 158 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)95607-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

378 Taxol® (paclitaxel) 225 mg/m2 b

378 Taxol® (paclitaxel) 225 mg/m2 by 3-hour infusion without G-CSF as a second line therapy in patients (PTS) with metastatic breast cancer (MBC)

✍ Ph. Bougnoux; R. Delva; D. Serin; M. Namer; G. Piot; J.P. Lotz; J.F. Ramée; E. V 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Randomized comparison of nab-paclitaxel

Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

✍ W. Gradishar; D. Krasnojon; S. Cheporov; A. Makhson; G. Manikhas; A. Clawson; P. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB